Study | Intervention | Location of primary tumor (colon/rectum) | Primary tumor size, mean (SD), cm | No. of CRLM, mean (SD) | CRLM location (unilober/bilobar) | CRLM size | R0 rate (liver/colorectum) | Neoadjuvant therapy | Mortality | Conversions |
---|---|---|---|---|---|---|---|---|---|---|
Ma et al. [23] | Lap | 7/5 | NR | 1.6 (0.9) | 7/5 | 3.73 ± 2.91 | 100/100 | 3 (25) | 0 | 0 |
Open | 7/5 | NR | 3.1 (1.8) | 5/2 | 3.02 ± 1.62 | 100/100 | 3 (25) | 0 |  | |
Ivanecz et al. [20] | Lap | 4/6 | NR | 1.4 (0.9) | 9/1 | 2.0  ± 1.2 | 100/100 | 7 (70) | 0 | 0 |
Open | 6/4 | NR | 1.4 (0.9) | 9/1 | 2.9 ± 1.5 | 100/100 | 3 (30) | 0 |  | |
Xu et al. [26] | Lap | 15/5 | 3.2 (1.0) | 6a | 18/2 | 2.99 ± 1.55 | 100/100 | 6 (30) | 0 | 0 |
Open | 15/5 | 3.8 (1.2) | 6 | 17/3 | 3.19 ± 1.53 | 100/100 | 4 (20) | 0 |  | |
Chen et al [16]. | Lap | NR/NR | 4.0 (2.0) | 4a | NR | 5.5 ± 4.2 | NR/NR | NR | 0 | 1 |
Open | NR/NR | 5.0 (3.0) | 3 | NR | 4.7 ± 3.7 | NR/NR | NR | 0 |  | |
Gorgun et al. [17] | Lap | 6/8 | 3.7 (0.7) | 1.6 (0.3) | 12/2 | 2.4 ± 0.7 | 86/NR | 6 (43) | 0 | 0 |
Open | 14/15 | 3.7 (0.5) | 2.1 ± 0.2 | 19/10 | 2.7 ± 0.2 | 93/NR | 19 (66) | 1 |  | |
Ratti et al [24]. | Lap | 13/12 | NR | 2.40 ± 1.27 | 13/12 | 3.65 ± 2.67 | 96/100 | 20 (80) | 0 | 1 |
Open | 27/23 | NR | 2.35 ± 1.34 | 27/23 | 3.94 ± 2.47 | 98/98 | 39 (78) | 0 |  | |
Tranchart et al. [25] | Lap | 48/41 | NR | 1.4 ± 0.6 | 78/11 | 2.9  ± 1.9 | 83/NR | 11 (12) | 2 | 6 |
Open | 51/38 | NR | 1.5 ± 0.7 | 81/8 | 2.8  ± 2.0 | 90/NR | 20 (22) | 0 |  | |
Lin et al [22]. | Lap | 3/4 | 5.3 (1.1) | 1.9 ± 0.9 | NR | 3.3  ± 1.8 | 100/NR | 3 (27) | 0 | 0 |
Open | 19/17 | 5.7 (1.9) | 2.1 ±  1.0 | NR | 4.2  ± 2.2 | 100/NR | 13 (36) | 0 |  | |
Jung et al [21]. | Lap | 18/6 | 5.23 (2.13) | NR | 23/1 | 2.81 ± 1.72 | 100/96 | NR | 0 | 0 |
Open | 16/8 | 5.56 (1.93) | NR | 18/6 | 3.23 ± 2.21 | 100/100 | NR | 0 |  | |
Hu et al [18]. | Lap | 8/5 | NR | NR | NR | 3.2 ± 1.0 | NR/NR | 0 (0) | 0 | 0 |
Open | 8/5 | NR | NR | NR | 3.5 ± 0.9 | NR/NR | 0 (0) | 0 |  | |
Huh et al [19]. | Lap | 7/13 | 4 (2–10) | 2 (1–7) | 17/3 | 2 (0.9–5.5) | 100/NR | NR | 0 | 0 |
Open | 11/9 | 4.7 (3–7) | 2 (1–8) | 16/4 | 2.4 (1–10) | 100/NR | NR | 0 |  | |
Chen et al [15]. | Lap | 0/23 | 2.5 (0.9) | NR | NR | 5.5 ± 1.2 | NR/NR | NR | 0 | 0 |
Open | 0/18 | 2.3 (1.0) | NR | NR | 5.6 ± 1.4 | NR/NR | NR | 0 |  |